Study Overview
Sex: All
Age: 18 Years / N/A
No Study Documents
Study Overview
Sex: All
Age: 18 Years / N/A
No Study Documents
Terminated
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Sex: All
Age: 18 Years / N/A
No Study Documents
Sex: All
Age: 18 Years / N/A
No Study Documents